InvestorsHub Logo
Followers 523
Posts 6631
Boards Moderated 1
Alias Born 07/24/2012

Re: None

Thursday, 10/25/2012 9:02:01 PM

Thursday, October 25, 2012 9:02:01 PM

Post# of 130503
As new and exciting proof-of-concept data for MANF in secondary therapeutic indications continues to be published by research laboratories throughout [i]Europe, China, Japan and North America, the value of our intellectual property ("IP") portfolio is steadily increasing. We are continually expanding our IP portfolio for MANF by filing and aggregating new patents.